Concomitant lansoprazole ameliorates cisplatin‐induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats
Biopharmaceutics & Drug Disposition · 2020-06 · 41 (6) · 239-247
DOI: 10.1002/bdd.2242 ↗At a glance
Journal article in Biopharmaceutics & Drug Disposition, published online on 2020-06-25. Written by Shun-Ichi Hiramatsu and 4 co-authors. Institution: Department of Clinical Pharmacy and Biopharmaceutics, Mie University Graduate School of Medicine, Tsu, Mie, Japan. Cited 15 times so far (Crossref); 38 references. Funded by: Japan Society for the Promotion of Science.
Abstract (original language)
Cisplatin is used widely for the treatment of multiple solid tumors. Cisplatin‐induced nephrotoxicity is caused by renal accumulation of cisplatin via human organic cation transporter 2 (hOCT2). As lansoprazole, a proton pump inhibitor, is known to inhibit hOCT2 activity, lansoprazole might ameliorate cisplatin‐induced nephrotoxicity. A previous study showed that concomitant lansoprazole administration ameliorated nephrotoxicity in patients receiving cisplatin. However, the detailed mechanism remains to be clarified. In the present study, the drug–drug interaction between lansoprazole and cisplatin was examined using hOCT2‐expressing cultured cells and rat renal slices. Moreover, the effect of lansoprazole on cisplatin‐induced nephrotoxicity and the pharmacokinetics of cisplatin in rats was investigated. In the uptake study, lansoprazole potently inhibited the uptake of cisplatin in hOCT2‐expressing cultured cells and rat renal slices. The in vivo rat study showed that concomitant lansoprazole significantly ameliorated cisplatin‐induced nephrotoxicity and reduced the renal accumulation of platinum up to approximately 60% of cisplatin alone at 72 h after cisplatin intraperitoneal administration. Furthermore, the renal uptake of platinum at 3 min after intravenous cisplatin administration in rats with cisplatin and lansoprazole decreased to 78% of rats with cisplatin alone. In addition, there was no significant difference in the plasma platinum concentration between rats treated with and without lansoprazole at 3 min after cisplatin intravenous administration. These findings suggested that concomitant lansoprazole ameliorated cisplatin‐induced nephrotoxicity by inhibiting rOCT2‐mediated cisplatin uptake in rats, thus decreasing cisplatin accumulation in the kidney. The present findings provided important information for the establishment of novel protective approaches to minimize cisplatin‐induced nephrotoxicity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Clinical Pharmacy and Biopharmaceutics, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
- Department of Pharmacy, Osaka University Hospital, Suita, Osaka, Japan.
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, Japan.
- Department of Pharmacy, Mie University Hospital, Tsu, Mie, Japan.
ORCID profiles: Kenji Ikemura
Funding
- Japan Society for the Promotion of Science
Cite
APA
Hiramatsu, S. I., Ikemura, K., Fujisawa, Y., Iwamoto, T., & Okuda, M. (2020). Concomitant lansoprazole ameliorates cisplatin‐induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats. Biopharmaceutics & Drug Disposition, 41(6), 239-247. https://doi.org/10.1002/bdd.2242
Vancouver
Hiramatsu SI, Ikemura K, Fujisawa Y, Iwamoto T, Okuda M. Concomitant lansoprazole ameliorates cisplatin‐induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats. Biopharmaceutics & Drug Disposition. 2020;41(6):239-247. doi:10.1002/bdd.2242
BibTeX
@article{Hiramatsu2020,
author = {Hiramatsu, Shun-Ichi and Ikemura, Kenji and Fujisawa, Yutaka and Iwamoto, Takuya and Okuda, Masahiro},
title = {Concomitant lansoprazole ameliorates cisplatin‐induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats},
journal = {Biopharmaceutics & Drug Disposition},
year = {2020},
volume = {41},
number = {6},
pages = {239--247},
doi = {10.1002/bdd.2242}
}
EUVIMED